These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 38948056)
1. PRL1 and PRL3 promote macropinocytosis via its lipid phosphatase activity. Ye Z; Ng CP; Liu H; Bao Q; Xu S; Zu D; He Y; Huang Y; Al-Aidaroos AQO; Guo K; Li J; Yaw LP; Xiong Q; Thura M; Zheng W; Guan F; Cheng X; Shi Y; Zeng Q Theranostics; 2024; 14(9):3423-3438. PubMed ID: 38948056 [TBL] [Abstract][Full Text] [Related]
2. Phosphatase activity, trimerization, and the C-terminal polybasic region are all required for PRL1-mediated cell growth and migration. Sun JP; Luo Y; Yu X; Wang WQ; Zhou B; Liang F; Zhang ZY J Biol Chem; 2007 Sep; 282(39):29043-29051. PubMed ID: 17656357 [TBL] [Abstract][Full Text] [Related]
3. Targeting PRL phosphatases in hematological malignancies. Xiao S; Chen H; Bai Y; Zhang ZY; Liu Y Expert Opin Ther Targets; 2024 Apr; 28(4):259-271. PubMed ID: 38653737 [TBL] [Abstract][Full Text] [Related]
4. PRL1 promotes cell migration and invasion by increasing MMP2 and MMP9 expression through Src and ERK1/2 pathways. Luo Y; Liang F; Zhang ZY Biochemistry; 2009 Mar; 48(8):1838-46. PubMed ID: 19199380 [TBL] [Abstract][Full Text] [Related]
5. Overexpression of phosphatase regenerating liver 3 in oesophageal squamous cell carcinoma associated with metastasis and its comparison with phosphatase regenerating liver 1. Lou X; Liu Y; Lei JY; Li H Cell Biol Int; 2012 Aug; 36(8):759-63. PubMed ID: 22551255 [TBL] [Abstract][Full Text] [Related]
6. Identification of PRL1 as a novel diagnostic and therapeutic target for castration-resistant prostate cancer by the Escherichia coli ampicillin secretion trap (CAST) method. Shinmei S; Sentani K; Hayashi T; Sakamoto N; Goto K; Oo HZ; Naito Y; Teishima J; Matsubara A; Oue N; Kuniyasu H; Yasui W Urol Oncol; 2014 Aug; 32(6):769-78. PubMed ID: 24968948 [TBL] [Abstract][Full Text] [Related]
7. PRL3 pseudophosphatase activity is necessary and sufficient to promote metastatic growth. Kozlov G; Funato Y; Chen YS; Zhang Z; Illes K; Miki H; Gehring K J Biol Chem; 2020 Aug; 295(33):11682-11692. PubMed ID: 32571875 [TBL] [Abstract][Full Text] [Related]
8. Discovery and Evaluation of PRL Trimer Disruptors for Novel Anticancer Agents. Bai Y; Yu ZH; Zhang ZY Methods Mol Biol; 2016; 1447():121-38. PubMed ID: 27514804 [TBL] [Abstract][Full Text] [Related]
9. MicroRNA-26a inhibits cell proliferation and invasion of cervical cancer cells by targeting protein tyrosine phosphatase type IVA 1. Dong J; Sui L; Wang Q; Chen M; Sun H Mol Med Rep; 2014 Sep; 10(3):1426-32. PubMed ID: 24939702 [TBL] [Abstract][Full Text] [Related]
10. RNAi‑mediated knockdown of PRL‑3 inhibits cell invasion and downregulates ERK 1/2 expression in the human gastric cancer cell line, SGC‑7901. Cao Y; Tu Y; Mei J; Li Z; Jie Z; Xu S; Xu L; Wang S; Xiong Y Mol Med Rep; 2013 Jun; 7(6):1805-11. PubMed ID: 23589069 [TBL] [Abstract][Full Text] [Related]
11. Interaction with tumor‑associated macrophages promotes PRL‑3‑induced invasion of colorectal cancer cells via MAPK pathway‑induced EMT and NF‑κB signaling‑induced angiogenesis. Zhang T; Liu L; Lai W; Zeng Y; Xu H; Lan Q; Su P; Chu Z Oncol Rep; 2019 May; 41(5):2790-2802. PubMed ID: 30864736 [TBL] [Abstract][Full Text] [Related]
12. PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation. Liang F; Liang J; Wang WQ; Sun JP; Udho E; Zhang ZY J Biol Chem; 2007 Feb; 282(8):5413-9. PubMed ID: 17192274 [TBL] [Abstract][Full Text] [Related]
13. Sequential breakdown of 3-phosphorylated phosphoinositides is essential for the completion of macropinocytosis. Maekawa M; Terasaka S; Mochizuki Y; Kawai K; Ikeda Y; Araki N; Skolnik EY; Taguchi T; Arai H Proc Natl Acad Sci U S A; 2014 Mar; 111(11):E978-87. PubMed ID: 24591580 [TBL] [Abstract][Full Text] [Related]
14. Phosphatase of regenerating liver 3 (PRL3) provokes a tyrosine phosphoproteome to drive prometastatic signal transduction. Walls CD; Iliuk A; Bai Y; Wang M; Tao WA; Zhang ZY Mol Cell Proteomics; 2013 Dec; 12(12):3759-77. PubMed ID: 24030100 [TBL] [Abstract][Full Text] [Related]
15. Chemotherapy induced PRL3 expression promotes cancer growth via plasma membrane remodeling and specific alterations of caveolae-associated signaling. Csoboz B; Gombos I; Tatrai E; Tovari J; Kiss AL; Horvath I; Vigh L Cell Commun Signal; 2018 Aug; 16(1):51. PubMed ID: 30157875 [TBL] [Abstract][Full Text] [Related]
16. PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein. Thura M; Al-Aidaroos AQ; Gupta A; Chee CE; Lee SC; Hui KM; Li J; Guan YK; Yong WP; So J; Chng WJ; Ng CH; Zhou J; Wang LZ; Yuen JSP; Ho HSS; Yi SM; Chiong E; Choo SP; Ngeow J; Ng MCH; Chua C; Yeo ESA; Tan IBH; Sng JXE; Tan NYZ; Thiery JP; Goh BC; Zeng Q Nat Commun; 2019 Jun; 10(1):2484. PubMed ID: 31171773 [TBL] [Abstract][Full Text] [Related]
17. Rab5 regulates macropinocytosis by recruiting the inositol 5-phosphatases OCRL and Inpp5b that hydrolyse PtdIns(4,5)P2. Maxson ME; Sarantis H; Volchuk A; Brumell JH; Grinstein S J Cell Sci; 2021 Apr; 134(7):. PubMed ID: 33722976 [TBL] [Abstract][Full Text] [Related]
18. Correlation of PRL3 expression with colorectal cancer progression. Leiphrakpam PD; Lazenby AJ; Smith LM; Brattain MG; Black JD; Wang J; Are C J Surg Oncol; 2021 Jan; 123(1):42-51. PubMed ID: 33179291 [TBL] [Abstract][Full Text] [Related]
19. PRL3 phosphatase active site is required for binding the putative magnesium transporter CNNM3. Zhang H; Kozlov G; Li X; Wu H; Gulerez I; Gehring K Sci Rep; 2017 Mar; 7(1):48. PubMed ID: 28246390 [TBL] [Abstract][Full Text] [Related]
20. Translational control of C-terminal Src kinase (Csk) expression by PRL3 phosphatase. Liang F; Luo Y; Dong Y; Walls CD; Liang J; Jiang HY; Sanford JR; Wek RC; Zhang ZY J Biol Chem; 2008 Apr; 283(16):10339-46. PubMed ID: 18268019 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]